Your browser doesn't support javascript.
Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
Westrop, Samantha J; Whitaker, Heather J; Powell, Annabel A; Power, Linda; Whillock, Corinne; Campbell, Helen; Simmons, Ruth; Warrener, Lenesha; Ramsay, Mary E; Ladhani, Shamez N; Brown, Kevin E; Amirthalingam, Gayatri.
  • Westrop SJ; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK. Electronic address: samantha.westrop@phe.gov.uk.
  • Whitaker HJ; Statistics, Modelling and Economics Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Powell AA; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Power L; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Whillock C; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Campbell H; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Simmons R; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Warrener L; Virus Reference Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Ramsay ME; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Ladhani SN; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK; Paediatric Infectious Diseases Research Group, St. George's University of London, Cranmer Terrace, London SW17 0RE, UK.
  • Brown KE; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Amirthalingam G; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
J Infect ; 84(5): 692-700, 2022 05.
Article in English | MEDLINE | ID: covidwho-1665191
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

There are limited data on immune responses to heterologous COVID-19 immunisation schedules, especially following an extended ≥12-week interval between doses.

METHODS:

SARS-CoV-2 infection-naïve and previously-infected adults receiving ChAd-BNT (ChAdOx1 nCoV-19, AstraZeneca followed by BNT162b2, Pfizer-BioNTech) or BNT-ChAd as part of the UK national immunisation programme provided blood samples at 30 days and 12 weeks after their second dose. Geometric mean concentrations (GMC) of anti-SARS-CoV-2 spike (S-antibody) and nucleoprotein (N-antibody) IgG antibodies and geometric mean ratios (GMR) were compared with a contemporaneous cohort receiving homologous ChAd-ChAd or BNT-BNT.

RESULTS:

During March-October 2021, 75,827 individuals were identified as having received heterologous vaccination, 9,489 invited to participate, 1,836 responded (19.3%) and 656 were eligible. In previously-uninfected adults, S-antibody GMC at 30 days post-second dose were lowest for ChAd-ChAd (862 [95% CI, 694 - 1069]) and significantly higher for ChAd-BNT (6233 [5522-7035]; GMR 6.29; [5.04-7.85]; p<0.001), BNT-ChAd (4776 [4066-5610]; GMR 4.55 [3.56-5.81]; p<0.001) and BNT-BNT (5377 [4596-6289]; GMR 5.66 [4.49-7.15]; p<0.001). By 12 weeks after dose two, S-antibody GMC had declined in all groups and remained significantly lower for ChAd-ChAd compared to ChAd-BNT (GMR 5.12 [3.79-6.92]; p<0.001), BNT-ChAd (GMR 4.1 [2.96-5.69]; p<0.001) and BNT-BNT (GMR 6.06 [4.32-8.50]; p<0.001). Previously infected adults had higher S-antibody GMC compared to infection-naïve adults at all time-points and with all vaccine schedules.

CONCLUSIONS:

These real-world findings demonstrate heterologous schedules with adenoviral-vector and mRNA vaccines are highly immunogenic and may be recommended after a serious adverse reaction to one vaccine product, or to increase programmatic flexibility where vaccine supplies are constrained.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Country/Region as subject: Europa Language: English Journal: J Infect Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Country/Region as subject: Europa Language: English Journal: J Infect Year: 2022 Document Type: Article